WILMS TUMOR MUTATIONAL SUBCLASSES CONVERGE TO DRIVE CCND2 OVEREXPRESSION

Area of Science:

• Oncology
• Genetics
• Developmental Biology

Background:

• Wilms tumor is the most common pediatric kidney cancer, with poor outcomes for high-risk cases.
• Existing sequencing data offer limited biological and clinical insights into Wilms tumor pathogenesis.
• Understanding Wilms tumor's molecular drivers is crucial for improving patient treatment.

Approach:

• Performed DNA and RNA sequencing on 94 Wilms tumors.
• Analyzed mutations to identify transcriptional alterations driving tumor progression.
• Investigated the role of specific mutated genes, such as DROSHA, in Wilms tumor development.

Key Points:

• Wilms tumor mutations cluster into four distinct classes with unique transcriptional signatures.
• Mutations in the microRNA processing enzyme DROSHA are common and impair microRNA maturation.
• DROSHA mutations lead to de-repression of target genes, halting differentiation and promoting proliferation via CCND2 overexpression.

Conclusions:

• Wilms tumor pathogenesis involves distinct mutational pathways converging on gene expression dysregulation.
• CCND2 overexpression, driven by multiple mutation classes, presents a potential therapeutic vulnerability.
• Further research into cell-cycle inhibitors could benefit patients with high-risk Wilms tumor.